News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
269,959 Results
Type
Article (14052)
Company Profile (107)
Press Release (255795)
Multimedia
Podcasts (57)
Webinars (13)
Section
Business (88184)
Career Advice (466)
Deals (15368)
Drug Delivery (68)
Drug Development (36665)
Employer Resources (49)
FDA (6334)
Job Trends (6218)
News (150494)
Policy (14101)
Tag
Academia (441)
Accelerated approval (6)
Adcomms (7)
Allergies (51)
Alliances (23320)
ALS (48)
Alzheimer's disease (443)
Antibody-drug conjugate (ADC) (62)
Approvals (6416)
Artificial intelligence (148)
Autoimmune disease (14)
Automation (6)
Bankruptcy (150)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (78)
Biotechnology (41)
Bladder cancer (27)
Brain cancer (23)
Breast cancer (116)
Cancer (943)
Cardiovascular disease (113)
Career advice (412)
Career pathing (12)
CAR-T (34)
CDC (5)
Cell therapy (114)
Cervical cancer (6)
Clinical research (31416)
Collaboration (509)
Compensation (242)
Complete response letters (24)
COVID-19 (771)
CRISPR (34)
C-suite (266)
Cystic fibrosis (49)
Data (1117)
Denatured (16)
Depression (24)
Diabetes (104)
Diagnostics (1346)
Digital health (4)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (78)
Drug pricing (91)
Drug shortages (12)
Duchenne muscular dystrophy (62)
Earnings (32936)
Editorial (15)
Employer branding (4)
Employer resources (44)
Events (38241)
Executive appointments (490)
FDA (7117)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (311)
Gene editing (54)
Generative AI (10)
Gene therapy (131)
GLP-1 (403)
Government (1361)
Grass and pollen (4)
Guidances (137)
Healthcare (3574)
HIV (7)
Huntington's disease (5)
IgA nephropathy (22)
Immunology and inflammation (54)
Immuno-oncology (3)
Indications (25)
Infectious disease (815)
Inflammatory bowel disease (63)
Inflation Reduction Act (7)
Influenza (18)
Intellectual property (75)
Interviews (59)
IPO (5909)
IRA (33)
Job creations (2055)
Job search strategy (373)
Kidney cancer (7)
Labor market (22)
Layoffs (197)
Leadership (6)
Legal (3444)
Liver cancer (21)
Longevity (6)
Lung cancer (138)
Lymphoma (84)
Machine learning (5)
Management (16)
Manufacturing (273)
MASH (53)
Medical device (1292)
Medtech (1294)
Mergers & acquisitions (9769)
Metabolic disorders (350)
Multiple sclerosis (33)
NASH (14)
Neurodegenerative disease (43)
Neuropsychiatric disorders (15)
Neuroscience (722)
NextGen: Class of 2025 (1588)
Non-profit (598)
Now hiring (13)
Obesity (189)
Opinion (133)
Ovarian cancer (29)
Pain (87)
Pancreatic cancer (30)
Parkinson's disease (55)
Partnered (8)
Patents (171)
Patient recruitment (71)
Peanut (12)
People (29364)
Pharmaceutical (64)
Pharmacy benefit managers (14)
Phase I (8172)
Phase II (13279)
Phase III (11945)
Pipeline (955)
Policy (114)
Postmarket research (1401)
Preclinical (3290)
Press Release (25)
Prostate cancer (67)
Psychedelics (12)
Radiopharmaceuticals (125)
Rare diseases (238)
Real estate (2648)
Recruiting (17)
Regulatory (10476)
Reports (15)
Research institute (568)
Resumes & cover letters (55)
Rett syndrome (3)
RNA editing (5)
RSV (11)
Schizophrenia (52)
Series A (56)
Series B (28)
Service/supplier (3)
Sickle cell disease (38)
Special edition (9)
Spinal muscular atrophy (77)
Sponsored (7)
Startups (1638)
State (2)
Stomach cancer (3)
Supply chain (40)
Tariffs (57)
The Weekly (39)
Vaccines (202)
Venture capital (22)
Weight loss (119)
Women's health (10)
Worklife (4)
Date
Today (43)
Last 7 days (151)
Last 30 days (758)
Last 365 days (10948)
2025 (7809)
2024 (12503)
2023 (14246)
2022 (19560)
2021 (20069)
2020 (19032)
2019 (14885)
2018 (11713)
2017 (13890)
2016 (13130)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
Location
Africa (316)
Alabama (16)
Alaska (1)
Arizona (67)
Arkansas (3)
Asia (20499)
Australia (2644)
California (2452)
Canada (1215)
China (398)
Colorado (99)
Connecticut (102)
Delaware (91)
Europe (40190)
Florida (476)
Georgia (54)
Hawaii (1)
Idaho (9)
Illinois (273)
India (25)
Indiana (183)
Iowa (1)
Japan (152)
Kansas (69)
Kentucky (17)
Louisiana (2)
Maine (2)
Maryland (351)
Massachusetts (2100)
Michigan (38)
Minnesota (133)
Mississippi (1)
Missouri (26)
Montana (8)
Nebraska (6)
Nevada (13)
New Hampshire (6)
New Jersey (1090)
New Mexico (7)
New York (704)
North Carolina (503)
North Dakota (2)
Northern California (1043)
Ohio (61)
Oklahoma (5)
Oregon (16)
Pennsylvania (589)
Puerto Rico (9)
Rhode Island (14)
South America (505)
South Carolina (5)
Southern California (1055)
Tennessee (43)
Texas (353)
United States (10068)
Utah (50)
Virginia (124)
Washington D.C. (40)
Washington State (164)
West Virginia (1)
Wisconsin (25)
269,959 Results for "dicerna pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition
Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. (Dicerna; Nasdaq: DRNA), announced on 18 November 2021, has been completed.
December 28, 2021
·
2 min read
Deals
Novo Nordisk to Acquire Dicerna
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that it has entered into a definitive agreement with Novo Nordisk under which Novo Nordisk will acquire Dicerna.
November 18, 2021
·
12 min read
Deals
Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m., Eastern Time, on December 24, 2021.
December 25, 2021
·
8 min read
Business
Dicerna Announces New Executive Leadership Appointments
Dicerna Pharmaceuticals, Inc. today announced the appointment of Rob Ciappenelli as Chief Strategy Officer
September 22, 2021
·
9 min read
Genetown
Dicerna to Participate in 16th Annual Citi Biopharma Conference
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., President and Chief Executive Officer, will participate in a virtual fireside chat at the 16th Annual Citi Biopharma Conference.
September 2, 2021
·
3 min read
Drug Development
Dicerna Initiates Phase 1 Clinical Trial of DCR-AUD, a Novel Investigational GalXC™ RNAi Therapeutic Candidate for the Treatment of Alcohol Use Disorder
Dicerna Pharmaceuticals, Inc today announced that it dosed the first subjects in its Phase 1 clinical trial to assess DCR-AUD, Dicerna’s investigational GalXC™ RNAi therapeutic in development for the treatment of alcohol use disorder (AUD).
September 28, 2021
·
9 min read
Business
Dicerna to Report Third Quarter 2021 Financial Results on Nov. 9, 2021
Dicerna Pharmaceuticals, Inc., a leading developer of investigational ribonucleic acid interference therapeutics, announced that the Company will release its third quarter 2021 financial results before market open on Tuesday, Nov. 9, 2021.
November 2, 2021
·
2 min read
Business
Dicerna Announces Third Quarter 2021 Financial Results and Provides a Business Update
Dicerna Announces Third Quarter 2021 Financial Results and Provides a Business Update
November 9, 2021
·
14 min read
Business
Dicerna to Report Second Quarter 2021 Financial Results on Aug. 9, 2021
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its second quarter 2021 financial results before market open on Monday, Aug. 9, 2021.
August 2, 2021
·
2 min read
Business
Dicerna Announces Second Quarter 2021 Financial Results and Provides a Business Update
Dicerna Pharmaceuticals, Inc. today reported its financial results for the quarter ended June 30, 2021 and provided a corporate update.
August 9, 2021
·
16 min read
1 of 26,996
Next
